1 |
0.9% normal saline (control) |
- |
- |
- |
- |
299 [1] 299 💬 |
2 |
0.9% sodium chloride (normal saline) |
Chloride ion |
[1] D02056 D02056 💬 |
- |
- |
006 [1] 6 💬 |
3 |
10% metronidazole ointment |
Metronidazole |
[3] D00409 D00409, D05016 D05016, D05017 D05017 💬 |
- |
- |
096 [1] 96 💬 |
4 |
19 nor vitamin d |
Vitamin D |
- |
- |
- |
013 [1] 13 💬 |
5 |
: immunoglobulina umana normale 10% per somministrazione endovenosa |
- |
- |
- |
- |
014 [1] 14 💬 |
6 |
[18f]-(e)-n-(3-iodoprop-2-enyl)-2b-carbofluoroethoxy-3b-(4'-methylphenyl)nortropane |
- |
- |
- |
- |
006 [1] 6 💬 |
7 |
[18f]nos |
- |
- |
- |
- |
006 [1] 6 💬 |
8 |
A novel synthetic, orally-administered, non-peptide small molecule, which acts as |
- |
- |
- |
- |
254 [1] 254 💬 |
9 |
A-f-a-f (novorapid-fiasp-novorapid-fiasp) |
- |
- |
- |
- |
299 [1] 299 💬 |
10 |
Administration of a high dose of desipramine |
Desipramine |
[2] D00812 D00812, D07791 D07791 💬 |
SLC6A2 [2] SLC6A2, SLC6A4 💬 |
Serotonergic synapse [2] Serotonergic synapse, Synaptic vesicle cycle |
156 [1] 156 💬 |
11 |
Administration of a low dose of desipramine |
Desipramine |
[2] D00812 D00812, D07791 D07791 💬 |
SLC6A2 [2] SLC6A2, SLC6A4 💬 |
Serotonergic synapse [2] Serotonergic synapse, Synaptic vesicle cycle |
156 [1] 156 💬 |
12 |
Administration of an ace-inhibitor or not |
- |
- |
- |
- |
210 [1] 210 💬 |
13 |
Alk-001 (no generic name) |
- |
- |
- |
- |
301 [1] 301 💬 |
14 |
Amikin, amiklin, amicacin, bb-k8, biklin, fabianol, kaminax, mikavir, novamin, pierami |
- |
- |
- |
- |
299 [1] 299 💬 |
15 |
Amikin®, amiklin, amicacin, bb-k8, biklin®, fabianol®, kaminax, mikavir, novamin®, pierami |
- |
- |
- |
- |
299 [1] 299 💬 |
16 |
Amlodipine |
Amlodipine |
[3] D00615 D00615, D02914 D02914, D07450 D07450 💬 |
CACNA1C [4] CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 |
Adrenergic signaling in cardiomyocytes [36] Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
051 [3] 51, 67, 298 💬 |
17 |
Amlodipine (drug) |
Amlodipine |
[3] D00615 D00615, D02914 D02914, D07450 D07450 💬 |
CACNA1C [4] CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 |
Adrenergic signaling in cardiomyocytes [36] Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
298 [1] 298 💬 |
18 |
Amlodipine gel |
Amlodipine |
[3] D00615 D00615, D02914 D02914, D07450 D07450 💬 |
CACNA1C [4] CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 |
Adrenergic signaling in cardiomyocytes [36] Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
051 [1] 51 💬 |
19 |
Amoxicillin, metronidazole and tetracycline |
Amoxicillin |
[7] D00201 D00201, D00229 D00229, D00409 D00409, D02925 D02925, D05016 D05016, D05017 D05017, D07452 D07452 💬 |
- |
- |
097 [1] 97 💬 |
20 |
Atazanavir (atv) + ritonavir (rtv), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (nrtis) |
Atazanavir |
[3] D00427 D00427, D01276 D01276, D07471 D07471 💬 |
- |
- |
265 [1] 265 💬 |
21 |
Atazanavir/ritonavir |
Atazanavir |
[3] D00427 D00427, D01276 D01276, D07471 D07471 💬 |
- |
- |
265 [1] 265 💬 |
22 |
Azithromycin + metronidazole |
Azithromycin |
[6] D00409 D00409, D02134 D02134, D05016 D05016, D05017 D05017, D06390 D06390, D07486 D07486 💬 |
- |
- |
096 [1] 96 💬 |
23 |
Aún no establecido |
- |
- |
- |
- |
053 [1] 53 💬 |
24 |
Behavioral: assessment of motor and non-motors symptoms of pd evaluation of hyper- and hypodopaminergic behaviors |
- |
- |
- |
- |
006 [1] 6 💬 |
25 |
Bia 9-1067 non-micronized |
BIA |
- |
- |
- |
006 [1] 6 💬 |
26 |
Bio-enhanced curcumin soft gelatin capsule |
Curcumin |
[2] D00115 D00115, D06892 D06892 💬 |
- |
- |
097 [1] 97 💬 |
27 |
Biological : i10e (human normal immunoglobulin for intravenous administration 100mg/ml) |
Human immunoglobulin G |
- |
- |
- |
014 [1] 14 💬 |
28 |
Biological: kiovig® (human normal immunoglobulin for intravenous administration 100mg/ml) |
Human immunoglobulin G |
- |
- |
- |
014 [1] 14 💬 |
29 |
Botox 200u in normal saline |
- |
- |
- |
- |
226 [1] 226 💬 |
30 |
Candesartan plus non-ccb agents |
Candesartan |
[1] D00522 D00522 💬 |
AGTR1 [1] AGTR1 💬 |
AGE-RAGE signaling pathway in diabetic complications [16] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
067 [1] 67 💬 |
31 |
Cas no.: 7758-16-9 |
- |
- |
- |
- |
166 [1] 166 💬 |
32 |
Catridecacog |
Catridecacog |
[1] D10532 D10532 💬 |
- |
- |
097 [2] 97, 288 💬 |
33 |
Celulas madre mesenquimales troncales adultas alogenicas de médula ósea no expandida |
- |
- |
- |
- |
274 [1] 274 💬 |
34 |
Clarithromycin (not used as of 4/2020) |
Clarithromycin |
[1] D00276 D00276 💬 |
- |
- |
006 [1] 6 💬 |
35 |
Coenzyme q-10 in normal control subjects |
Ubidecarenone |
[1] D01065 D01065 💬 |
- |
- |
086 [1] 86 💬 |
36 |
Control intervention (no dexamethasone) |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
046 [1] 46 💬 |
37 |
Corticosteroid and non-biological agents. |
- |
- |
- |
- |
046 [1] 46 💬 |
38 |
Cysteine |
Cysteine |
[2] D00026 D00026, D02326 D02326 💬 |
- |
- |
006 [11] 6 , 13, 19, 34, 84, 85, 88, 90, 254, 296, 310 💬 |
39 |
Cysteine hydrochloride |
Cysteine |
[2] D00026 D00026, D02326 D02326 💬 |
- |
- |
254 [1] 254 💬 |
40 |
Células mesenquimales troncales adultas alogénicas de médula ósea no expandidas |
- |
- |
- |
- |
274 [1] 274 💬 |
41 |
Células mesenquimales troncales adultas alogénicas de médula ósea no expandidas(ref cruzada pei nº 12-088) |
- |
- |
- |
- |
274 [1] 274 💬 |
42 |
Ddavp (desmopressin) |
Desmopressin |
[2] D00291 D00291, D02235 D02235 💬 |
AVPR2 [2] AVPR2, F8 💬 |
Complement and coagulation cascades [4] Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
288 [1] 288 💬 |
43 |
Desipramine |
Desipramine |
[2] D00812 D00812, D07791 D07791 💬 |
SLC6A2 [2] SLC6A2, SLC6A4 💬 |
Serotonergic synapse [2] Serotonergic synapse, Synaptic vesicle cycle |
006 [4] 6 , 17, 120, 156 💬 |
44 |
Desipramine (dmi) |
Desipramine |
[2] D00812 D00812, D07791 D07791 💬 |
SLC6A2 [2] SLC6A2, SLC6A4 💬 |
Serotonergic synapse [2] Serotonergic synapse, Synaptic vesicle cycle |
006 [2] 6 , 17 💬 |
45 |
Desmopressin |
Desmopressin |
[2] D00291 D00291, D02235 D02235 💬 |
AVPR2 [2] AVPR2, F8 💬 |
Complement and coagulation cascades [4] Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
006 [5] 6 , 64, 72, 225, 288 💬 |
46 |
Desmopressin acetat |
Desmopressin |
[2] D00291 D00291, D02235 D02235 💬 |
AVPR2 [2] AVPR2, F8 💬 |
Complement and coagulation cascades [4] Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
006 [1] 6 💬 |
47 |
Desmopressin acetate |
Acetate |
[2] D00291 D00291, D02235 D02235 💬 |
AVPR2 [2] AVPR2, F8 💬 |
Complement and coagulation cascades [4] Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
064 [2] 64, 288 💬 |
48 |
Desmopressin acetate trihydrate |
Acetate |
[2] D00291 D00291, D02235 D02235 💬 |
AVPR2 [2] AVPR2, F8 💬 |
Complement and coagulation cascades [4] Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
225 [1] 225 💬 |
49 |
Desmopressin intranasal |
Desmopressin |
[2] D00291 D00291, D02235 D02235 💬 |
AVPR2 [2] AVPR2, F8 💬 |
Complement and coagulation cascades [4] Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
072 [1] 72 💬 |
50 |
Desmopressin oral melt |
Desmopressin |
[2] D00291 D00291, D02235 D02235 💬 |
AVPR2 [2] AVPR2, F8 💬 |
Complement and coagulation cascades [4] Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
072 [1] 72 💬 |
51 |
Device: no orthosis |
- |
- |
- |
- |
070 [1] 70 💬 |
52 |
Device: nocturnal oxygen , nocturnal bi-level positive pressure ventilation |
Oxygen |
[1] D00003 D00003 💬 |
- |
- |
299 [1] 299 💬 |
53 |
Device: non invasive ventilation |
- |
- |
- |
- |
299 [1] 299 💬 |
54 |
Device: noninvasive ventilation |
- |
- |
- |
- |
299 [1] 299 💬 |
55 |
Device: novel allergen-specific immune signature directed approach to dietary elimination therapy |
- |
- |
- |
- |
098 [1] 98 💬 |
56 |
Device: occlusive non adherent dressing |
- |
- |
- |
- |
036 [1] 36 💬 |
57 |
Device: reciprocating procedure device (rpd) - avanca re no. 1091001 |
- |
- |
- |
- |
046 [1] 46 💬 |
58 |
Dexrazoxane (drz) plus mitoxantrone (mx) |
Dexrazoxane |
[3] D02166 D02166, D03730 D03730, D08224 D08224 💬 |
TOP2A [2] TOP2A, TOP2B 💬 |
Platinum drug resistance [1] Platinum drug resistance |
013 [1] 13 💬 |
59 |
Diagnostic test: nociceptor flexor reflex |
- |
- |
- |
- |
149 [1] 149 💬 |
60 |
Droxidopa |
Droxidopa |
[1] D01277 D01277 💬 |
ADRA1A [9] ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 |
AMPK signaling pathway [13] AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
005 [3] 5 , 6 , 17 💬 |
61 |
Droxidopa 100 mg [northera] |
Droxidopa |
[1] D01277 D01277 💬 |
ADRA1A [9] ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 |
AMPK signaling pathway [13] AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 [1] 6 💬 |
62 |
Experimental (non immunosuppressive symptomatic treatment (nist) and rituximab) |
Rituximab |
[1] D02994 D02994 💬 |
MS4A1 [1] MS4A1 💬 |
Hematopoietic cell lineage [1] Hematopoietic cell lineage |
222 [1] 222 💬 |
63 |
Extavia (interferon beta-1b), novartis pharma ag |
Human interferon beta |
[1] D00746 D00746 💬 |
IFNAR1 [2] IFNAR1, IFNAR2 💬 |
Coronavirus disease - COVID-19 [18] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
013 [1] 13 💬 |
64 |
Extended-release quetiapine fumarate |
Quetiapine |
[2] D00458 D00458, D08456 D08456 💬 |
DRD2 [2] DRD2, HTR2A 💬 |
Alcoholism [11] Alcoholism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, cAMP signaling pathway |
013 [1] 13 💬 |
65 |
F-a-f-a (fiasp-novorapid-fiasp-novorapid) |
- |
- |
- |
- |
299 [1] 299 💬 |
66 |
Freeze-dried sulfonated human normal immunoglobulin (ggs) |
Human immunoglobulin G |
- |
- |
- |
014 [3] 14, 43, 45 💬 |
67 |
From august 2020 'no additional treatment' |
- |
- |
- |
- |
051 [1] 51 💬 |
68 |
Ga-68-dota-noc |
- |
- |
- |
- |
084 [1] 84 💬 |
69 |
Gallium68-dota-noc |
- |
- |
- |
- |
085 [1] 85 💬 |
70 |
Gamma-secretase/notch signalling pathway inhibitor ro4929097 |
- |
- |
- |
- |
074 [1] 74 💬 |
71 |
Gelatin |
Gelatin |
[2] D00115 D00115, D06892 D06892 💬 |
- |
- |
028 [4] 28, 78, 97, 269 💬 |
72 |
Ginger |
Ginger |
[1] D06744 D06744 💬 |
- |
- |
046 [1] 46 💬 |
73 |
Glatiramer acetate 20 mg, with mitoxantrone |
Acetate |
[3] D02166 D02166, D04318 D04318, D08224 D08224 💬 |
HLA-A [22] HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G, TOP2A, TOP2B 💬 |
Allograft rejection [33] Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Platinum drug resistance, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 [1] 13 💬 |
74 |
Glucocorticoids (permitted,not necessary) |
- |
- |
- |
- |
046 [1] 46 💬 |
75 |
Green tea leaf |
Green tea leaf |
[1] D06903 D06903 💬 |
- |
- |
017 [1] 17 💬 |
76 |
Gsk2018682 cd3 non-micronised tablet |
- |
- |
- |
- |
013 [1] 13 💬 |
77 |
Gsk2018682 cd3 non-micronised tablet in fed state |
- |
- |
- |
- |
013 [1] 13 💬 |
78 |
Hemin |
Hemin |
[1] D10003 D10003 💬 |
ALAS1 [2] ALAS1, ALAS2 💬 |
Biosynthesis of cofactors [4] Biosynthesis of cofactors, Glycine, serine and threonine metabolism, Metabolic pathways, Porphyrin and chlorophyll metabolism |
254 [1] 254 💬 |
79 |
Hemin for injection |
Hemin |
[1] D10003 D10003 💬 |
ALAS1 [2] ALAS1, ALAS2 💬 |
Biosynthesis of cofactors [4] Biosynthesis of cofactors, Glycine, serine and threonine metabolism, Metabolic pathways, Porphyrin and chlorophyll metabolism |
254 [1] 254 💬 |
80 |
Human normal 10% immunoglobulin for intravenous administration |
- |
- |
- |
- |
014 [1] 14 💬 |
81 |
Human normal 10% immunoglobulin for intravenous administrationn |
- |
- |
- |
- |
014 [1] 14 💬 |
82 |
Human normal immunoglobulin |
Human immunoglobulin G |
- |
- |
- |
011 [9] 11, 13, 14, 43, 45, 50, 51, 63, 65 💬 |
83 |
Human normal immunoglobulin (iv) |
Human immunoglobulin G |
- |
- |
- |
011 [4] 11, 14, 63, 65 💬 |
84 |
Human normal immunoglobulin (ivig) |
Human immunoglobulin G |
- |
- |
- |
050 [2] 50, 65 💬 |
85 |
Human normal immunoglobulin (scig) |
Human immunoglobulin G |
- |
- |
- |
014 [1] 14 💬 |
86 |
Human normal immunoglobulin (subcutaneous - intramuscular immunoglobulin) |
Human immunoglobulin G |
- |
- |
- |
065 [1] 65 💬 |
87 |
Human normal immunoglobulin (subcutaneous) |
Human immunoglobulin G |
- |
- |
- |
065 [1] 65 💬 |
88 |
Human normal immunoglobulin for |
Human immunoglobulin G |
- |
- |
- |
065 [1] 65 💬 |
89 |
Human normal immunoglobulin for intravenous (iv) administration |
Human immunoglobulin G |
- |
- |
- |
051 [1] 51 💬 |
90 |
Human normal immunoglobulin for intravenous administration |
Human immunoglobulin G |
- |
- |
- |
014 [3] 14, 51, 65 💬 |
91 |
Human normal immunoglobulin for intravenous use |
Human immunoglobulin G |
- |
- |
- |
063 [2] 63, 65 💬 |
92 |
Human normal immunoglobulin for intravenous use (ivig) |
Human immunoglobulin G |
- |
- |
- |
065 [1] 65 💬 |
93 |
Human normal immunoglobulin for intrvenous use |
Human immunoglobulin G |
- |
- |
- |
063 [1] 63 💬 |
94 |
Human normal immunoglobulin for subcutaneous administration |
Human immunoglobulin G |
- |
- |
- |
051 [2] 51, 65 💬 |
95 |
Human normal immunoglobulin for subcutaneous administration (igsc) |
Human immunoglobulin G |
- |
- |
- |
065 [1] 65 💬 |
96 |
Human normal immunoglobulin g (igg > 98% purity) |
Human immunoglobulin G |
- |
- |
- |
014 [3] 14, 63, 65 💬 |
97 |
Human normal immunoglobulin g (igg) |
Human immunoglobulin G |
- |
- |
- |
011 [1] 11 💬 |
98 |
Human normal immunoglogulin (ivig) |
Human immunoglobulin G |
- |
- |
- |
050 [1] 50 💬 |
99 |
Human recombinant tissue non-specific alkaline phosphatase fusion protein |
Alkaline Phosphatase |
- |
- |
- |
172 [1] 172 💬 |
100 |
Immunoglobulin g1, anti (protein nogo a) (human mus musculus monoclonal heavy |
- |
- |
- |
- |
002 [1] 2 💬 |
101 |
Immunoglobulin g1, anti (protein nogo a) (human mus musculus monoclonal heavy chain), disulfide with human mus musculus monoclonal light chain, dimer |
- |
- |
- |
- |
002 [1] 2 💬 |
102 |
Immunoglobulina umana normale per somministrazione endovenosa |
- |
- |
- |
- |
014 [1] 14 💬 |
103 |
Immunoglobulins, normal human |
- |
- |
- |
- |
065 [1] 65 💬 |
104 |
Immunoglobulins, normal human, for extravascular adm. |
- |
- |
- |
- |
014 [1] 14 💬 |
105 |
Immunoglobulins, normal human, for intravascular adm. |
- |
- |
- |
- |
014 [2] 14, 15 💬 |
106 |
Inhaled nitric oxide |
Nitric Oxide |
[1] D00074 D00074 💬 |
- |
- |
085 [2] 85, 86 💬 |
107 |
Inhaled nitric oxide & inopulse delivery |
Nitric Oxide |
[1] D00074 D00074 💬 |
- |
- |
086 [1] 86 💬 |
108 |
Inhaled nitric oxide - 30 mcg/kg ibw/hr |
Nitric Oxide |
[1] D00074 D00074 💬 |
- |
- |
085 [1] 85 💬 |
109 |
Inhaled nitric oxide 5,10,15 mcg/kg ibw/hr |
Nitric Oxide |
[1] D00074 D00074 💬 |
- |
- |
085 [1] 85 💬 |
110 |
Inhaled nitric oxide 75 mcg/kg ibw/hr |
Nitric Oxide |
[1] D00074 D00074 💬 |
- |
- |
085 [2] 85, 86 💬 |
111 |
Inhaled no with pulsed delivery |
- |
- |
- |
- |
086 [1] 86 💬 |
112 |
Injection of normal saline |
- |
- |
- |
- |
006 [1] 6 💬 |
113 |
Inn not available |
- |
- |
- |
- |
019 [2] 19, 46 💬 |
114 |
Inn not available yet |
- |
- |
- |
- |
222 [1] 222 💬 |
115 |
Inn not yet proposed |
- |
- |
- |
- |
193 [1] 193 💬 |
116 |
Intravenous and oral n-acetyl cysteine |
Cysteine |
[2] D00026 D00026, D02326 D02326 💬 |
- |
- |
006 [1] 6 💬 |
117 |
Istradefylline |
Istradefylline |
[1] D04641 D04641 💬 |
ADORA2A [1] ADORA2A 💬 |
Alcoholism [7] Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
006 [1] 6 💬 |
118 |
Istradefylline ( kw-6002) |
Istradefylline |
[1] D04641 D04641 💬 |
ADORA2A [1] ADORA2A 💬 |
Alcoholism [7] Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
006 [1] 6 💬 |
119 |
Istradefylline (kw-6002) |
Istradefylline |
[1] D04641 D04641 💬 |
ADORA2A [1] ADORA2A 💬 |
Alcoholism [7] Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
006 [1] 6 💬 |
120 |
Istradefylline 20 mg |
Istradefylline |
[1] D04641 D04641 💬 |
ADORA2A [1] ADORA2A 💬 |
Alcoholism [7] Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
006 [1] 6 💬 |
121 |
Istradefylline 20 mg or 40 mg |
Istradefylline |
[1] D04641 D04641 💬 |
ADORA2A [1] ADORA2A 💬 |
Alcoholism [7] Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
006 [1] 6 💬 |
122 |
Istradefylline 40 mg |
Istradefylline |
[1] D04641 D04641 💬 |
ADORA2A [1] ADORA2A 💬 |
Alcoholism [7] Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
006 [1] 6 💬 |
123 |
Kw-6002 (istradefylline) |
Istradefylline |
[1] D04641 D04641 💬 |
ADORA2A [1] ADORA2A 💬 |
Alcoholism [7] Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
006 [1] 6 💬 |
124 |
Leflunomide (permitted, not necessary) |
Leflunomide |
[1] D00749 D00749 💬 |
DHODH [1] DHODH 💬 |
Biosynthesis of cofactors [3] Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism |
046 [1] 46 💬 |
125 |
Lenadogene nolparvovec |
- |
- |
- |
- |
302 [1] 302 💬 |
126 |
Levobupivacaine |
Levobupivacaine |
[2] D01287 D01287, D08116 D08116 💬 |
SCN1A [5] SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes [3] Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
046 [1] 46 💬 |
127 |
Levonorgestrel |
Levonorgestrel |
[1] D00950 D00950 💬 |
PGR [1] PGR 💬 |
Breast cancer [4] Breast cancer, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation |
013 [1] 13 💬 |
128 |
Loestrin (norethindrone acetate and ethinyl estradiol) |
Acetate |
[11] D00105 D00105, D00182 D00182, D00554 D00554, D00953 D00953, D01413 D01413, D01617 D01617, D01953 D01953, D04061 D04061, D04063 D04063, D04064 D04064, D04065 D04065 💬 |
ESR1 [3] ESR1, ESR2, PGR 💬 |
Breast cancer [11] Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
299 [1] 299 💬 |
129 |
Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol) |
Acetate |
[11] D00105 D00105, D00182 D00182, D00554 D00554, D00953 D00953, D01413 D01413, D01617 D01617, D01953 D01953, D04061 D04061, D04063 D04063, D04064 D04064, D04065 D04065 💬 |
ESR1 [3] ESR1, ESR2, PGR 💬 |
Breast cancer [11] Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
046 [2] 46, 49 💬 |
130 |
Lopinavir/ritonavir |
Lopinavir |
[2] D00427 D00427, D01425 D01425 💬 |
- |
- |
265 [1] 265 💬 |
131 |
Lopinavir/ritonavir + nevirapine |
Lopinavir |
[3] D00427 D00427, D00435 D00435, D01425 D01425 💬 |
- |
- |
265 [1] 265 💬 |
132 |
Lopinavir/ritonavir + zidovudine + lamivudine |
Lamivudine |
[4] D00353 D00353, D00413 D00413, D00427 D00427, D01425 D01425 💬 |
- |
- |
265 [1] 265 💬 |
133 |
Methotrexate(mtx) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol |
Methotrexate |
[2] D00142 D00142, D02115 D02115 💬 |
DHFR [2] DHFR, DHFR2 💬 |
Antifolate resistance [5] Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
046 [1] 46 💬 |
134 |
Methotrexate(mtx) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol. |
Methotrexate |
[2] D00142 D00142, D02115 D02115 💬 |
DHFR [2] DHFR, DHFR2 💬 |
Antifolate resistance [5] Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
046 [1] 46 💬 |
135 |
Metronidazole |
Metronidazole |
[3] D00409 D00409, D05016 D05016, D05017 D05017 💬 |
- |
- |
046 [8] 46, 51, 63, 94, 95, 96, 97, 291 💬 |
136 |
Metronidazole capsule 50 mg |
Metronidazole |
[3] D00409 D00409, D05016 D05016, D05017 D05017 💬 |
- |
- |
097 [1] 97 💬 |
137 |
Mitoxantrone |
Mitoxantrone |
[2] D02166 D02166, D08224 D08224 💬 |
TOP2A [2] TOP2A, TOP2B 💬 |
Platinum drug resistance [1] Platinum drug resistance |
013 [1] 13 💬 |
138 |
Monotherapy (lopinavir/ritonavir) |
Lopinavir |
[2] D00427 D00427, D01425 D01425 💬 |
- |
- |
265 [1] 265 💬 |
139 |
Monotherapy (lopinavir/ritonavir) + abc/3tc |
Lopinavir |
[2] D00427 D00427, D01425 D01425 💬 |
- |
- |
265 [1] 265 💬 |
140 |
N acetyl cysteine |
Cysteine |
[2] D00026 D00026, D02326 D02326 💬 |
- |
- |
006 [2] 6 , 19 💬 |
141 |
N-acetyl cysteine |
Cysteine |
[2] D00026 D00026, D02326 D02326 💬 |
- |
- |
013 [7] 13, 19, 34, 85, 88, 296, 310 💬 |
142 |
N-acetyl cysteine (nac) |
Cysteine |
[2] D00026 D00026, D02326 D02326 💬 |
- |
- |
090 [1] 90 💬 |
143 |
N-acetyl-cysteine |
Cysteine |
[2] D00026 D00026, D02326 D02326 💬 |
- |
- |
084 [1] 84 💬 |
144 |
Neoral soft gelatin capsules |
Gelatin |
[2] D00115 D00115, D06892 D06892 💬 |
- |
- |
097 [2] 97, 269 💬 |
145 |
Nitric oxide |
Nitric Oxide |
[1] D00074 D00074 💬 |
- |
- |
046 [8] 46, 85, 86, 98, 210, 251, 294, 299 💬 |
146 |
Nitric oxide 160 ppm |
Nitric Oxide |
[1] D00074 D00074 💬 |
- |
- |
299 [1] 299 💬 |
147 |
Nitric oxide for inhalation |
Nitric Oxide |
[1] D00074 D00074 💬 |
- |
- |
086 [2] 86, 299 💬 |
148 |
Nitric oxide generated by the geno nitrosyl delivery system |
Nitric Oxide |
[1] D00074 D00074 💬 |
- |
- |
086 [1] 86 💬 |
149 |
Nitric oxide plus oxygen |
Nitric Oxide |
[2] D00003 D00003, D00074 D00074 💬 |
- |
- |
086 [1] 86 💬 |
150 |
Nitric oxide supplement |
Nitric Oxide |
[1] D00074 D00074 💬 |
- |
- |
251 [1] 251 💬 |
151 |
No |
- |
- |
- |
- |
046 [3] 46, 62, 299 💬 |
152 |
Nolpitantium besylate |
- |
- |
- |
- |
097 [1] 97 💬 |
153 |
Nomegestrol |
Nomegestrol |
[1] D07222 D07222 💬 |
PGR [1] PGR 💬 |
Breast cancer [4] Breast cancer, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation |
013 [1] 13 💬 |
154 |
Nomegestrol acetate |
Acetate |
[2] D07222 D07222, D08281 D08281 💬 |
PGR [1] PGR 💬 |
Breast cancer [4] Breast cancer, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation |
013 [1] 13 💬 |
155 |
Non applicabile |
- |
- |
- |
- |
051 [1] 51 💬 |
156 |
Non applicable |
- |
- |
- |
- |
010 [2] 10, 19 💬 |
157 |
Non as of yet |
- |
- |
- |
- |
097 [1] 97 💬 |
158 |
Non atg conditioning regimen |
- |
- |
- |
- |
060 [1] 60 💬 |
159 |
Non propietry, therefore n/a |
- |
- |
- |
- |
051 [1] 51 💬 |
160 |
Non-anti-tnf biologics |
- |
- |
- |
- |
046 [2] 46, 271 💬 |
161 |
Non-biologic anti-rheumatic drugs |
- |
- |
- |
- |
046 [1] 46 💬 |
162 |
Non-biologic disease modifying anti-rheumatic drug (dmard) |
- |
- |
- |
- |
046 [1] 46 💬 |
163 |
Non-biologic dmards |
- |
- |
- |
- |
046 [2] 46, 86 💬 |
164 |
Non-biological dmard's |
- |
- |
- |
- |
046 [1] 46 💬 |
165 |
Non-biological dmards |
- |
- |
- |
- |
046 [1] 46 💬 |
166 |
Non-myeloablative hematopoietic stem cell transplantation |
- |
- |
- |
- |
093 [1] 93 💬 |
167 |
Non-nucleoside reverse transcriptase inhibitors |
- |
- |
- |
- |
265 [1] 265 💬 |
168 |
Non-pegylated interferon |
- |
- |
- |
- |
013 [1] 13 💬 |
169 |
Non-steroidal anti-inflammatory drug |
- |
- |
- |
- |
046 [1] 46 💬 |
170 |
Non-steroidal anti-inflammatory drug (nsaid) |
- |
- |
- |
- |
046 [1] 46 💬 |
171 |
Non-steroidal anti-inflammatory drugs |
- |
- |
- |
- |
046 [1] 46 💬 |
172 |
Non-steroidal anti-inflammatory drugs (nsaids) |
- |
- |
- |
- |
107 [1] 107 💬 |
173 |
Nonbiologic dmards of investigator's choice |
- |
- |
- |
- |
046 [1] 46 💬 |
174 |
None |
- |
- |
- |
- |
046 [14] 46, 65, 78, 84, 85, 96, 97, 140, 160, 161, 171, 231, 271, 299 💬 |
175 |
None as of yet |
- |
- |
- |
- |
046 [1] 46 💬 |
176 |
None assigned |
- |
- |
- |
- |
231 [2] 231, 299 💬 |
177 |
None at this time |
- |
- |
- |
- |
096 [2] 96, 140 💬 |
178 |
None given |
- |
- |
- |
- |
097 [1] 97 💬 |
179 |
Nordiflex |
- |
- |
- |
- |
078 [1] 78 💬 |
180 |
Nordilet® |
- |
- |
- |
- |
078 [1] 78 💬 |
181 |
Norditropin |
- |
- |
- |
- |
078 [1] 78 💬 |
182 |
Norditropin 24 iu |
- |
- |
- |
- |
195 [1] 195 💬 |
183 |
Norditropin flexpro 10 mg |
- |
- |
- |
- |
078 [1] 78 💬 |
184 |
Norditropin flexpro 10 mg/1.5 ml |
- |
- |
- |
- |
078 [1] 78 💬 |
185 |
Norditropin growth hormone |
Somatotropin |
[1] D02691 D02691 💬 |
GHR [1] GHR 💬 |
Cytokine-cytokine receptor interaction [5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
078 [1] 78 💬 |
186 |
Norditropin nordiflex® |
- |
- |
- |
- |
078 [1] 78 💬 |
187 |
Norditropin nordiflex® 10 mg/1.5 ml |
- |
- |
- |
- |
078 [1] 78 💬 |
188 |
Norditropin nordiflex® 10mg/1.5 ml |
- |
- |
- |
- |
078 [1] 78 💬 |
189 |
Norditropin simplex |
- |
- |
- |
- |
078 [1] 78 💬 |
190 |
Norditropin simplexx |
- |
- |
- |
- |
003 [4] 3 , 78, 193, 195 💬 |
191 |
Norditropin simplexx (5mg/1,5 ml) (inn:somatropin) |
Somatotropin |
[1] D02691 D02691 💬 |
GHR [1] GHR 💬 |
Cytokine-cytokine receptor interaction [5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
078 [1] 78 💬 |
192 |
Norditropin simplexx (growth hormone) |
Somatotropin |
[1] D02691 D02691 💬 |
GHR [1] GHR 💬 |
Cytokine-cytokine receptor interaction [5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
078 [1] 78 💬 |
193 |
Norditropin simplexx 10 mg |
- |
- |
- |
- |
078 [1] 78 💬 |
194 |
Norditropin simplexx 15 mg/1.5 ml |
- |
- |
- |
- |
003 [1] 3 💬 |
195 |
Norditropin simplexx 5mg/1.5ml |
- |
- |
- |
- |
078 [1] 78 💬 |
196 |
Norditropin® |
- |
- |
- |
- |
078 [1] 78 💬 |
197 |
Norditropin® flexpro® |
- |
- |
- |
- |
078 [1] 78 💬 |
198 |
Norditropin® flexpro® pen |
- |
- |
- |
- |
078 [1] 78 💬 |
199 |
Norditropin® simplexx® 5 mg/1.5ml |
- |
- |
- |
- |
078 [1] 78 💬 |
200 |
Norepinephrine |
Norepinephrine |
[2] D00076 D00076, D05206 D05206 💬 |
ADRA1A [9] ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 |
AMPK signaling pathway [13] AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
022 [1] 22 💬 |
201 |
Norethindrone |
Norethisterone |
[2] D00182 D00182, D00953 D00953 💬 |
PGR [1] PGR 💬 |
Breast cancer [4] Breast cancer, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation |
013 [4] 13, 46, 49, 299 💬 |
202 |
Norgestimate |
Norgestimate |
[1] D05209 D05209 💬 |
PGR [1] PGR 💬 |
Breast cancer [4] Breast cancer, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation |
299 [1] 299 💬 |
203 |
Normal human immunoglobulin g |
Human immunoglobulin G |
- |
- |
- |
065 [1] 65 💬 |
204 |
Normal saline |
- |
- |
- |
- |
006 [16] 6 , 17, 22, 36, 46, 49, 60, 70, 94, 96, 210, 211, 226, 276, 296, 299 💬 |
205 |
Normal saline 0.9% infusion solution |
- |
- |
- |
- |
022 [1] 22 💬 |
206 |
Normal saline enema |
- |
- |
- |
- |
097 [1] 97 💬 |
207 |
Normal saline for injection |
- |
- |
- |
- |
013 [1] 13 💬 |
208 |
Normal saline instillation |
- |
- |
- |
- |
226 [1] 226 💬 |
209 |
Normal saline iv, salt tablets |
- |
- |
- |
- |
299 [1] 299 💬 |
210 |
Normal saline solution |
- |
- |
- |
- |
299 [1] 299 💬 |
211 |
Normal saline: |
- |
- |
- |
- |
299 [1] 299 💬 |
212 |
Normix |
- |
- |
- |
- |
096 [1] 96 💬 |
213 |
Normix*ad 12cpr riv 200mg |
- |
- |
- |
- |
096 [1] 96 💬 |
214 |
Norspan |
- |
- |
- |
- |
046 [1] 46 💬 |
215 |
Northera |
- |
- |
- |
- |
006 [1] 6 💬 |
216 |
Nortriptyline |
Nortriptyline |
[2] D00816 D00816, D08288 D08288 💬 |
SLC6A2 [2] SLC6A2, SLC6A4 💬 |
Serotonergic synapse [2] Serotonergic synapse, Synaptic vesicle cycle |
006 [2] 6 , 226 💬 |
217 |
Nortriptyline hydrochloride |
Nortriptyline |
[2] D00816 D00816, D08288 D08288 💬 |
SLC6A2 [2] SLC6A2, SLC6A4 💬 |
Serotonergic synapse [2] Serotonergic synapse, Synaptic vesicle cycle |
006 [1] 6 💬 |
218 |
Norudca |
- |
- |
- |
- |
094 [1] 94 💬 |
219 |
Norursodeoxycholic acid |
norUrsodeoxycholic acid |
- |
- |
- |
094 [1] 94 💬 |
220 |
Norvir |
- |
- |
- |
- |
265 [2] 265, 299 💬 |
221 |
Norvir 100 mg film-coated tablets |
- |
- |
- |
- |
299 [1] 299 💬 |
222 |
Novamin |
- |
- |
- |
- |
299 [1] 299 💬 |
223 |
Novantrone |
- |
- |
- |
- |
013 [1] 13 💬 |
224 |
Novantrone*inf 2mg/ml 5ml |
- |
- |
- |
- |
013 [1] 13 💬 |
225 |
Novartis pharmaceuticals corporation |
- |
- |
- |
- |
013 [1] 13 💬 |
226 |
Novatrex |
- |
- |
- |
- |
013 [1] 13 💬 |
227 |
Novo rapid |
- |
- |
- |
- |
299 [1] 299 💬 |
228 |
Novo rapid insulin (novonordisk) |
- |
- |
- |
- |
299 [1] 299 💬 |
229 |
Novolin-r insulin |
- |
- |
- |
- |
127 [1] 127 💬 |
230 |
Novolog insulin |
- |
- |
- |
- |
299 [1] 299 💬 |
231 |
Novonorm 0.5 mg |
- |
- |
- |
- |
299 [1] 299 💬 |
232 |
Novonorm 1 mg |
- |
- |
- |
- |
299 [1] 299 💬 |
233 |
Novonorm 2 mg |
- |
- |
- |
- |
299 [1] 299 💬 |
234 |
Novorapid / humalog short acting insulin |
- |
- |
- |
- |
299 [1] 299 💬 |
235 |
Novorapid 100 u/ml, solution for injection in a vial. novorapid penfill 100 u/ml, solution for injection in a cartridge. novorapid flexpen 100 u/ml, solution for injection in a pre-filled pen. |
- |
- |
- |
- |
299 [1] 299 💬 |
236 |
Novorapid aspartate |
- |
- |
- |
- |
299 [1] 299 💬 |
237 |
Nox-e36 |
- |
- |
- |
- |
049 [1] 49 💬 |
238 |
Noxafil |
- |
- |
- |
- |
060 [3] 60, 65, 299 💬 |
239 |
Noxafil - 40 mg/ml sospensione orale uso orale flacone (vetro) 105 ml 1 flacone |
- |
- |
- |
- |
299 [1] 299 💬 |
240 |
Noxafil - oral suspension 40 mg/ml |
- |
- |
- |
- |
299 [1] 299 💬 |
241 |
Noxafil 100 mg |
- |
- |
- |
- |
299 [1] 299 💬 |
242 |
Noxafil 40 mg/ml oral solution |
- |
- |
- |
- |
065 [1] 65 💬 |
243 |
Noxafil gastro resistant tablets |
- |
- |
- |
- |
060 [1] 60 💬 |
244 |
Noxafil® |
- |
- |
- |
- |
060 [2] 60, 299 💬 |
245 |
Nsaids (permitted,not necessary) |
- |
- |
- |
- |
046 [1] 46 💬 |
246 |
Ortho-cyclen, ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg |
Estradiol |
[10] D00105 D00105, D00554 D00554, D01413 D01413, D01617 D01617, D01953 D01953, D04061 D04061, D04063 D04063, D04064 D04064, D04065 D04065, D05209 D05209 💬 |
ESR1 [3] ESR1, ESR2, PGR 💬 |
Breast cancer [11] Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
299 [1] 299 💬 |
247 |
Ortho-novum |
- |
- |
- |
- |
046 [2] 46, 49 💬 |
248 |
Ortho-novum 777 |
- |
- |
- |
- |
049 [1] 49 💬 |
249 |
Ortho-novum® 1/35 |
- |
- |
- |
- |
046 [1] 46 💬 |
250 |
Other non steroidal anti-inflammatory drugs (nsaids) except etodolac |
Etodolac |
[1] D00315 D00315 💬 |
PTGS2 [1] PTGS2 💬 |
Alzheimer disease [22] Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
046 [1] 46 💬 |
251 |
Other non-selective nsaids |
- |
- |
- |
- |
271 [1] 271 💬 |
252 |
Other non-sponsor pancreatic enzyme replacement therapy |
- |
- |
- |
- |
299 [1] 299 💬 |
253 |
Other: antigen (wheat base soy sauce) spray |
Wheat |
[1] D06902 D06902 💬 |
- |
- |
098 [1] 98 💬 |
254 |
Other: control group(normal saline) |
- |
- |
- |
- |
097 [1] 97 💬 |
255 |
Other: dietary intervention with no-carrageenan diet |
- |
- |
- |
- |
097 [1] 97 💬 |
256 |
Other: fractional exhaled no (feno) |
- |
- |
- |
- |
096 [1] 96 💬 |
257 |
Other: mitoxantrone - immunomodulator |
Mitoxantrone |
[2] D02166 D02166, D08224 D08224 💬 |
TOP2A [2] TOP2A, TOP2B 💬 |
Platinum drug resistance [1] Platinum drug resistance |
013 [1] 13 💬 |
258 |
Other: no active treatment |
- |
- |
- |
- |
274 [1] 274 💬 |
259 |
Other: no anti-inflammatory treatment |
- |
- |
- |
- |
271 [1] 271 💬 |
260 |
Other: no device |
- |
- |
- |
- |
013 [1] 13 💬 |
261 |
Other: no doxycycline |
Doxycycline |
[5] D00307 D00307, D02129 D02129, D03903 D03903, D03904 D03904, D07876 D07876 💬 |
- |
- |
299 [1] 299 💬 |
262 |
Other: no enzyme therapy |
- |
- |
- |
- |
298 [1] 298 💬 |
263 |
Other: no intervention |
- |
- |
- |
- |
070 [1] 70 💬 |
264 |
Other: no intervention: standard of care |
- |
- |
- |
- |
085 [1] 85 💬 |
265 |
Other: no it treatment |
- |
- |
- |
- |
019 [1] 19 💬 |
266 |
Other: no msdmds therapy (control) |
- |
- |
- |
- |
013 [1] 13 💬 |
267 |
Other: no pancreatic enzyme replacement therapy |
- |
- |
- |
- |
299 [1] 299 💬 |
268 |
Other: no plasma exchange |
- |
- |
- |
- |
043 [2] 43, 44 💬 |
269 |
Other: no treatment |
- |
- |
- |
- |
053 [2] 53, 256 💬 |
270 |
Other: no treatment arm |
- |
- |
- |
- |
013 [1] 13 💬 |
271 |
Other: no treatment given |
- |
- |
- |
- |
078 [1] 78 💬 |
272 |
Other: non impact aerobics |
- |
- |
- |
- |
013 [1] 13 💬 |
273 |
Other: non-hormonal period |
- |
- |
- |
- |
299 [1] 299 💬 |
274 |
Other: non-motor symptoms |
- |
- |
- |
- |
006 [1] 6 💬 |
275 |
Other: noninvasive actigraphy monitor |
Methamidophos |
- |
- |
- |
086 [1] 86 💬 |
276 |
Other: nordic walking (only osteoporosis group) |
- |
- |
- |
- |
006 [1] 6 💬 |
277 |
Other: normal (control) diet |
- |
- |
- |
- |
240 [1] 240 💬 |
278 |
Other: normal diet |
- |
- |
- |
- |
096 [1] 96 💬 |
279 |
Other: normal saline |
- |
- |
- |
- |
013 [4] 13, 222, 226, 280 💬 |
280 |
Other: normal saline for injection |
- |
- |
- |
- |
084 [1] 84 💬 |
281 |
Other: oral nitric oxide testing |
Nitric Oxide |
[1] D00074 D00074 💬 |
- |
- |
098 [1] 98 💬 |
282 |
Other: sham (no implant) |
- |
- |
- |
- |
090 [1] 90 💬 |
283 |
Other: sterile normal saline (0.9% nacl) |
- |
- |
- |
- |
231 [1] 231 💬 |
284 |
Other: wheat flour |
Wheat |
[1] D06902 D06902 💬 |
- |
- |
266 [1] 266 💬 |
285 |
Patients' existing non-steroidal anti-inflammatory drug (nsaid) at approved doses |
- |
- |
- |
- |
046 [1] 46 💬 |
286 |
Pk-merz® 200mg/500ml inj(amantadine) , normal saline 500ml inj |
Amantadine |
[2] D00777 D00777, D07441 D07441 💬 |
GRIN1 [5] GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 |
Alcoholism [20] Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
006 [1] 6 💬 |
287 |
Posaconazole |
Posaconazole |
[1] D02555 D02555 💬 |
- |
- |
060 [3] 60, 65, 299 💬 |
288 |
Posaconazole (psz) |
Posaconazole |
[1] D02555 D02555 💬 |
- |
- |
065 [1] 65 💬 |
289 |
Prednison 5, 20 léciva por. tablet nob |
- |
- |
- |
- |
050 [1] 50 💬 |
290 |
Prednison 5, 20 léciva por. tablet nob. |
- |
- |
- |
- |
050 [1] 50 💬 |
291 |
Procedure: alcohol wipes vs. no alcohol wipes |
Ethanol |
[4] D00068 D00068, D02798 D02798, D04855 D04855, D06542 D06542 💬 |
- |
- |
013 [1] 13 💬 |
292 |
Procedure: audiological and ear, nose and throat examination |
- |
- |
- |
- |
078 [1] 78 💬 |
293 |
Procedure: exhaled nitric oxide |
Nitric Oxide |
[1] D00074 D00074 💬 |
- |
- |
299 [1] 299 💬 |
294 |
Procedure: exhaled nitric oxide assessment |
Nitric Oxide |
[1] D00074 D00074 💬 |
- |
- |
046 [1] 46 💬 |
295 |
Procedure: iv deployment of csvf in sterile normal saline iv solution |
- |
- |
- |
- |
085 [2] 85, 229 💬 |
296 |
Procedure: large bore (19g) histologic needle biopsy of the mediastinal lymph nodes |
- |
- |
- |
- |
084 [1] 84 💬 |
297 |
Procedure: no celiac block |
- |
- |
- |
- |
298 [1] 298 💬 |
298 |
Procedure: no gas |
- |
- |
- |
- |
086 [2] 86, 88 💬 |
299 |
Procedure: non-myeloablative high dose immunosuppressive therapy conditioning (hdit) |
- |
- |
- |
- |
049 [1] 49 💬 |
300 |
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation |
- |
- |
- |
- |
028 [6] 28, 51, 60, 62, 65, 285 💬 |
301 |
Quetiapine |
Quetiapine |
[2] D00458 D00458, D08456 D08456 💬 |
DRD2 [2] DRD2, HTR2A 💬 |
Alcoholism [11] Alcoholism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, cAMP signaling pathway |
006 [2] 6 , 13 💬 |
302 |
Rebif new formulation non titrated |
- |
- |
- |
- |
013 [1] 13 💬 |
303 |
Recombinant human somatotropin |
Somatotropin |
[1] D02691 D02691 💬 |
GHR [1] GHR 💬 |
Cytokine-cytokine receptor interaction [5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
078 [2] 78, 236 💬 |
304 |
Regular novolin r |
- |
- |
- |
- |
006 [1] 6 💬 |
305 |
Rhgh norditropin® flexpro® pen (34 µg/kg) |
Somatotropin |
[1] D02691 D02691 💬 |
GHR [1] GHR 💬 |
Cytokine-cytokine receptor interaction [5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
078 [1] 78 💬 |
306 |
Rifampicin |
Rifampicin |
[1] D00211 D00211 💬 |
- |
- |
006 [5] 6 , 17, 46, 93, 299 💬 |
307 |
Rifampin 300mg bid + istradefylline 40mg day 8 only |
Istradefylline |
[2] D00211 D00211, D04641 D04641 💬 |
ADORA2A [1] ADORA2A 💬 |
Alcoholism [7] Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
006 [1] 6 💬 |
308 |
Ritonavir |
Ritonavir |
[1] D00427 D00427 💬 |
- |
- |
002 [3] 2 , 86, 265 💬 |
309 |
Ritonavir (norvir) |
Ritonavir |
[1] D00427 D00427 💬 |
- |
- |
265 [1] 265 💬 |
310 |
Rokan (r) novo 120 mg |
- |
- |
- |
- |
018 [1] 18 💬 |
311 |
Ropivacaine plus normal saline |
Ropivacaine |
[2] D04048 D04048, D08490 D08490 💬 |
SCN1A [5] SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes [3] Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
070 [1] 70 💬 |
312 |
Saquinavir and ritonavir |
Ritonavir |
[3] D00427 D00427, D00429 D00429, D01160 D01160 💬 |
- |
- |
086 [1] 86 💬 |
313 |
Sativex oromucosal spray (non-marketed) |
- |
- |
- |
- |
013 [1] 13 💬 |
314 |
Somatotropin |
Somatotropin |
[1] D02691 D02691 💬 |
GHR [1] GHR 💬 |
Cytokine-cytokine receptor interaction [5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
003 [3] 3 , 78, 236 💬 |
315 |
Sterile normal saline (0.9% nacl) |
- |
- |
- |
- |
062 [3] 62, 234, 254 💬 |
316 |
Sterile normal saline for intravenous use |
- |
- |
- |
- |
085 [2] 85, 229 💬 |
317 |
Systemic non-biological treatments |
- |
- |
- |
- |
046 [2] 46, 271 💬 |
318 |
Tafamidis meglumine 20 mg soft gelatin capsules |
Gelatin |
[4] D00115 D00115, D01796 D01796, D06892 D06892, D09673 D09673 💬 |
TTR [1] TTR 💬 |
Thyroid hormone synthesis [1] Thyroid hormone synthesis |
028 [1] 28 💬 |
319 |
Tafamidis meglumine 20mg soft gelatin capsule (clinical trial image) |
Gelatin |
[4] D00115 D00115, D01796 D01796, D06892 D06892, D09673 D09673 💬 |
TTR [1] TTR 💬 |
Thyroid hormone synthesis [1] Thyroid hormone synthesis |
028 [1] 28 💬 |
320 |
Tafamidis meglumine 20mg soft gelatin capsule (commerical image) |
Gelatin |
[4] D00115 D00115, D01796 D01796, D06892 D06892, D09673 D09673 💬 |
TTR [1] TTR 💬 |
Thyroid hormone synthesis [1] Thyroid hormone synthesis |
028 [1] 28 💬 |
321 |
Takecab tablets + amoxicillin + clarithromycin (first-line eradication) takecab tablets + amoxicillin + metronidazole (second-line eradication) |
Amoxicillin |
[7] D00229 D00229, D00276 D00276, D00409 D00409, D02925 D02925, D05016 D05016, D05017 D05017, D07452 D07452 💬 |
- |
- |
063 [1] 63 💬 |
322 |
Tamoxifen |
Tamoxifen |
[2] D00966 D00966, D08559 D08559 💬 |
ESR1 [2] ESR1, ESR2 💬 |
Breast cancer [9] Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
002 [4] 2 , 86, 113, 227 💬 |
323 |
Tamoxifen 20mg hexal® filmtabletten |
Tamoxifen |
[2] D00966 D00966, D08559 D08559 💬 |
ESR1 [2] ESR1, ESR2 💬 |
Breast cancer [9] Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
113 [1] 113 💬 |
324 |
Tamoxifen 40 mg daily for one year |
Tamoxifen |
[2] D00966 D00966, D08559 D08559 💬 |
ESR1 [2] ESR1, ESR2 💬 |
Breast cancer [9] Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
002 [1] 2 💬 |
325 |
Tamoxifen citrate |
Tamoxifen |
[2] D00966 D00966, D08559 D08559 💬 |
ESR1 [2] ESR1, ESR2 💬 |
Breast cancer [9] Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
113 [1] 113 💬 |
326 |
The investigational medicinal product (imp) may be labelled as either pf-04236921 106 mg/vial, clonal sc lyophilized form” or pf-04236921 powder for injection, 106 mg/vial”. supplies labelled with either nomenclature are equivalent. |
- |
- |
- |
- |
096 [1] 96 💬 |
327 |
There is no recommended inn |
- |
- |
- |
- |
065 [1] 65 💬 |
328 |
Tnf-a antagonists, non-tnfs, dmard non-biologics |
- |
- |
- |
- |
046 [2] 46, 271 💬 |
329 |
Topotecan |
Topotecan |
[2] D02168 D02168, D08618 D08618 💬 |
- |
- |
025 [1] 25 💬 |
330 |
Triamcinolone acetonide and normal saline solution |
Triamcinolone |
[5] D00385 D00385, D00983 D00983, D00984 D00984, D00985 D00985, D06216 D06216 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
070 [1] 70 💬 |
331 |
Ustekinumab iv - nonresponder - ustekinumab 90mg sc (mp) |
Ustekinumab |
[1] D09214 D09214 💬 |
IL12A [3] IL12A, IL12B, IL23A 💬 |
African trypanosomiasis [26] African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
096 [1] 96 💬 |
332 |
Wheat |
Wheat |
[1] D06902 D06902 💬 |
- |
- |
098 [2] 98, 266 💬 |
333 |
Zofran - no intubation |
- |
- |
- |
- |
098 [1] 98 💬 |